Mesoblast(NASDAQ) MESO

Market Cap$2.07B

Since IPO (2005)+90%

5 Year+26%

1 Year-6%

1 Month-6%

Premium Feature

Moneyball Superscore

63/100

$15.95

+3.00%

+0.47Today

After hours$15.94-$0.01 (-0.06%)

Mesoblast last closing stock price
Metric	Price	Date
Last close	USD 15.92	2026-09-22

Mesoblast stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+8.01%	USD 14.74	2026-09-15
1 month	-6.35%	USD 17.00	2026-08-21
3 month	+2.38%	USD 15.55	2026-06-24
Year to date	-11.75%	USD 18.04	2025-12-31
1 year	-5.52%	USD 16.85	2025-09-22
3 year	+541.94%	USD 2.48	2023-09-22
5 year	+26.35%	USD 12.60	2021-09-23
Since inception	+89.9%	USD 8.15	2005-12-15

Mesoblast Financials at a Glance

Market Cap

$2.07B

Revenue (TTM)

$120.79M

Net Income (TTM)

-$57.50M

EPS (TTM)

-$0.45

P/E Ratio

-35.74

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$15.95

Volume

Open

$15.51

Price

$15.95

Volume

Open

$15.51

Previous Close

$15.92

Daily Range

$15.46 - $16.03

52-Week Range

$13.05 - $21.50

Estimated Earnings Date

Mar 4, 2027

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$15.95

Volume

Open

$15.51

Previous Close

$15.92

Daily Range

$15.46 - $16.03

52-Week Range

$13.05 - $21.50

Estimated Earnings Date

Mar 4, 2027

MESO News

Physician going over results with patient

Why Mesoblast Stock Plummeted on Friday

Jon QuastDec 18, 2020

Why Mesoblast Stock Is Tanking Today

Keith SpeightsDec 15, 2020

Scientist in lab looking through microscope

Why Mesoblast Stock Is Blasting Off Today

Keith SpeightsNov 20, 2020

Page 1

MESO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mesoblast

Mesoblast Limited is a biopharmaceutical firm focused on developing and commercializing allogeneic cell-based therapies. The company operates globally, addressing various medical conditions through its proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells.

Products and Services

Remestemcel-L for severe, steroid-refractory acute graft versus host disease
Rexlemestrocel-L targeting advanced chronic heart failure
MPC-06-ID for chronic low back pain from degenerative disc disease

Growth Outlook

Several product candidates are in Phase III clinical trials, indicating strong pipeline potential
Strategic partnerships enhance market reach and distribution capabilities
Focus on addressing unmet medical needs in diverse therapeutic areas

Financial Highlights

Recent quarterly revenue of $34.5 million shows growth compared to previous quarters
Cash and cash equivalents stand at $102.9 million, providing operational stability
Gross profit margin of 78.3% reflects strong product demand and pricing power

Mesoblast Limited is positioned in the biotechnology sector, with a focus on innovative therapies that address significant health challenges. The company's ongoing clinical trials and strategic partnerships are critical for its growth trajectory. Recent financial performance indicates a solid revenue stream and a healthy cash position, which are essential for funding further research and development. The emphasis on regenerative medicine and cell-based therapies aligns with current trends in healthcare, making Mesoblast a noteworthy entity in the biopharmaceutical landscape.

AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

108

CEO

Silviu Itescu, PhD

Website

www.mesoblast.com

Headquarters

Melbourne, VIC 3000, AU

MESO Financials

Key Financial Metrics (TTM)

Gross Margin

78.30%

Operating Margin

-96.11%

Net Income Margin

-46.79%

Return on Equity

-10.06%

Return on Capital

-7.40%

Return on Assets

-7.44%

Earnings Yield

-2.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.07B

Shares Outstanding

129.85M

Volume

Avg. Volume

228.47K

Financials (TTM)

Gross Profit

$96.22M

Operating Income

-$118.11M

EBITDA

-$45.01M

Operating Cash Flow

-$41.32M

Capital Expenditure

-$1.04M

Free Cash Flow

-$42.36M

Cash & ST Invst.

$102.91M

Total Debt

$127.33M

Mesoblast Performance Analysis

Mesoblast annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-06-30	USD 7,467,164	-26.9%
2024	2024-06-30	USD 5,923,635	-20.7%
2025	2025-06-30	USD 17,168,763	189.8%
2026	2026-06-30	USD 120,787,178	603.5%

Mesoblast sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-09-30	265.6%
Q2	2025-12-31	N/A
Q3	2026-03-31	34.2%
Q4	2026-06-30	1.6%

Mesoblast annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-06-30	USD -1.05	-21.6%
2024	2024-06-30	USD -0.89	-14.4%
2025	2025-06-30	USD -0.84	-5.6%
2026	2026-06-30	USD -0.45	-47.2%

Mesoblast sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-09-30	27.2%
Q2	2025-12-31	N/A
Q3	2026-03-31	56.8%
Q4	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

$34.99M

+398.4%

Gross Profit

$49.32M

+404.0%

Gross Margin

1.41%

N/A

Market Cap

$2.07B

N/A

Market Cap/Employee

$19.14M

N/A

Employees

108

N/A

Net Income

-$8.67M

+68.0%

EBITDA

-$9.97M

+49.2%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

$102.91M

-36.1%

Total Debt

$127.33M

-0.6%

Accounts Receivable

$57.08M

+283.9%

Inventory

$28.11M

+26.4%

Long Term Debt

$113.71M

+59.4%

Short Term Debt

$13.63M

-76.0%

Return on Assets

-7.44%

N/A

Return on Invested Capital

-17.07%

N/A

Free Cash Flow

-$6.95M

+53.5%

Operating Cash Flow

-$6.74M

+54.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$6.10+0.49%

GPCRStructure Therapeutics Inc.

GPCRStructure Therapeutics Inc.$36.91+0.27%

OCULOcular Therapeutix, Inc.

OCULOcular Therapeutix, Inc.$10.50+5.11%

VRDNViridian Therapeutics, Inc.

VRDNViridian Therapeutics, Inc.$22.12+2.50%

QUREuniQure N.V.

QUREuniQure N.V.$45.28+2.19%

EWTXEdgewise Therapeutics, Inc.

EWTXEdgewise Therapeutics, Inc.$44.51-0.29%

COGTCogent Biosciences, Inc.

COGTCogent Biosciences, Inc.$32.63+1.97%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

IUSBiShares Trust - iShares Core Universal Usd Bond ETF

IUSBiShares Trust - iShares Core Universal Usd Bond ETF$44.92+0.07%

MBBiShares Trust - iShares Mbs ETF

MBBiShares Trust - iShares Mbs ETF$91.45-0.15%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$32.42-7.09%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$151.95+7.13%

NOKNokia

NOKNokia$10.82-1.10%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$80.83+2.43%

GRMLGreenland Mines

GRMLGreenland Mines$14.15+50.21%

Questions About MESO

What is the current price of Mesoblast?

Mesoblast is trading at $15.92 per share.

What is the 52-week range for Mesoblast?

Over the past 52 weeks, Mesoblast has traded between $13.05 and $21.50.

How much debt does Mesoblast have?

As of the most recent reporting period, Mesoblast reported total debt of $127.33M.

How much cash does Mesoblast have on hand?

Mesoblast reported $102.91M in cash and cash equivalents in its most recent financial results.

What is Mesoblast’s dividend yield?

Mesoblast does not currently have a dividend yield.

Mesoblast(NASDAQ) MESO

Mesoblast Financials at a Glance

MESO News

Why Shares of Mesoblast Are Down Monday

Why Shares of Mesoblast Are Plunging Friday

Why Mesoblast Limited Stock Is Jumping Today

Why Mesoblast Limited Is Rising Today

Why Mesoblast Stock Skyrocketed Today

Why Mesoblast Stock Plummeted on Friday

Why Mesoblast Stock Is Tanking Today

Why Mesoblast Stock Is Blasting Off Today

MESO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Mesoblast

MESO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Mesoblast Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MESO

What is the current price of Mesoblast?

What is the 52-week range for Mesoblast?

How much debt does Mesoblast have?

How much cash does Mesoblast have on hand?

What is Mesoblast’s dividend yield?

Premium Investing Services